Literature DB >> 19699179

NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis.

Mylène Gilleron1, Xavier Marechal, David Montaigne, Jessica Franczak, Remi Neviere, Steve Lancel.   

Abstract

Cumulative doses of doxorubicin, a potent anticancer drug, lead to serious myocardial dysfunction. Numerous mechanisms including apoptosis have been proposed to account for its cardiotoxicity. Cardiac apoptosis induced by doxorubicin has been related to excessive reactive oxygen species production by the mitochondrial NADH dehydrogenase. Here, we explored whether doxorubicin treatment activates other superoxide anion generating systems such as the NADPH oxidases, membrane-embedded flavin-containing enzymes, and whether the subsequent oxidative stress contributes to apoptosis. We showed that doxorubicin treatment of rat cardiomyoblasts H9c2 triggers increases in caspase-3 like activity and hypoploid cells, both common features of apoptosis. Doxorubicin exposure also leads to a rapid superoxide production through NADPH oxidase activation. Inhibition of these enzymes using diphenyliodonium and apocynin reduces doxorubicin-induced reactive oxygen species production, caspase-3 like activity and sub-G1 cell population. In conclusion, NADPH oxidases participate to doxorubicin-induced cardiac apoptosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19699179     DOI: 10.1016/j.bbrc.2009.08.085

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  34 in total

1.  Influence of silencing soluble epoxide hydrolase with RNA interference on cardiomyocytes apoptosis induced by doxorubicin.

Authors:  Guangsheng Du; Jiagao Lv; Li He; Yexin Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-06-14

Review 2.  Doxorubicin-Induced Cardiomyopathy in Children.

Authors:  Trevi R Mancilla; Brian Iskra; Gregory J Aune
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

3.  Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy.

Authors:  Laura A A Gilliam; Jennifer S Moylan; Leigh Ann Callahan; Marius P Sumandea; Michael B Reid
Journal:  Muscle Nerve       Date:  2011-01       Impact factor: 3.217

Review 4.  NADPH oxidases and cardiac remodelling.

Authors:  Adam Nabeebaccus; Min Zhang; Ajay M Shah
Journal:  Heart Fail Rev       Date:  2011-01       Impact factor: 4.214

Review 5.  Imaging of early modification in cardiomyopathy: the doxorubicin-induced model.

Authors:  Mohamed Aissiou; Delphine Périé; Farida Cheriet; Nagib S Dahdah; Caroline Laverdière; Daniel Curnier
Journal:  Int J Cardiovasc Imaging       Date:  2013-06-07       Impact factor: 2.357

6.  Mitochondrial superoxide mediates doxorubicin-induced keratinocyte apoptosis through oxidative modification of ERK and Bcl-2 ubiquitination.

Authors:  Sudjit Luanpitpong; Pithi Chanvorachote; Ubonthip Nimmannit; Stephen S Leonard; Christian Stehlik; Liying Wang; Yon Rojanasakul
Journal:  Biochem Pharmacol       Date:  2012-03-24       Impact factor: 5.858

7.  Protective effect of PACAP against doxorubicin-induced cell death in cardiomyocyte culture.

Authors:  Boglarka Racz; Dora Reglodi; Gabriella Horvath; Andras Szigeti; Borbala Balatonyi; Erzsebet Roth; Gyorgy Weber; Nasri Alotti; Gabor Toth; Balazs Gasz
Journal:  J Mol Neurosci       Date:  2010-04-20       Impact factor: 3.444

8.  ALDH2 attenuates Dox-induced cardiotoxicity by inhibiting cardiac apoptosis and oxidative stress.

Authors:  Yawen Gao; Yan Xu; Songwen Hua; Shenghua Zhou; Kangkai Wang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

9.  Histamine 2 receptor antagonism elicits protection against doxorubicin-induced cardiotoxicity in rodent model.

Authors:  Sundar Kumar Kondru; Ajay Godwin Potnuri; Lingesh Allakonda; Prasad Konduri
Journal:  Mol Cell Biochem       Date:  2017-09-08       Impact factor: 3.396

10.  Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms.

Authors:  Almudena Cascales; Francisco Pastor-Quirante; Beatriz Sánchez-Vega; Ginés Luengo-Gil; Javier Corral; Guzmán Ortuño-Pacheco; Vicente Vicente; Francisco Ayala de la Peña
Journal:  Oncologist       Date:  2013-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.